Theratechnologies Inc (TSE:TH) – Equities research analysts at National Bank Financial issued their FY2019 EPS estimates for shares of Theratechnologies in a report released on Wednesday. National Bank Financial analyst E. Leno forecasts that the company will post earnings of $0.43 per share for the year. National Bank Financial currently has a “Outperform” rating and a $8.75 target price on the stock.
Shares of Theratechnologies (TSE TH) opened at C$7.00 on Monday. Theratechnologies has a 12-month low of C$3.41 and a 12-month high of C$8.72. The company has a market capitalization of $536.84, a PE ratio of -36.84 and a beta of 0.35.
Theratechnologies Inc is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.